The New York, N.Y.-based eClinical company Medidata Solutions has been awarded a major contract from AstraZeneca to provide the company with its Medidata Rave electronic data capture (EDC), replacing AstraZeneca’s present in-house system.
AstraZeneca initially will incorporate Medi-data’s platform on 50 to 55 phase II through IV global studies; however, its ultimate goal is to use Rave on all studies within the next several years.
“I think we are seeing a trend, where companies who had internal systems, like AstraZeneca, are making decisions to go with a product that is off the shelf. The other side of the equation for a company such as AstraZeneca, is what is the overhead of trying to maintain an internally developed product,” Ed Ikeguchi, co-founder and chief medical officer at Medidata told CWWeekly. You can read CenterWatch complete in depth coverage of the deal in the December 4th issue of CWWeekly.
